Ongoing SCENESSE® Clinical Trials

Clinuvel is currently conducting one clinical trial of SCENESSE® (afamelanotide 16mg) as a repigmentation therapy in generalised vitiligo. A physician-led study of SCENESSE® in Hailey-Hailey Disease commenced in early 2014.

In February 2012 Clinuvel filed a marketing authorisation application (MAA) for SCENESSE® with the European Medicines Agency (EMA) for the orphan disease erythropoietic protoporphria (EPP). In October 2014 SCENESSE® was recommended for marketing authorisation by the EMA for the prevention of symptoms in adults with EPP.

Clinuvel Stock Ticker

Quick Links